- Home
- LSPD vs RCKT Comparison
LSPD vs RCKT Comparison
Compare LSPD & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSPD | RCKT |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 340.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSPD | RCKT |
|---|---|---|
| Price | $12.15 | $3.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | $13.63 | ★ $29.12 |
| AVG Volume (30 Days) | 425.6K | ★ 1.9M |
| Earning Date | 02-05-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,157,458,000.00 | N/A |
| Revenue This Year | $15.25 | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.24 | N/A |
| 52 Week Low | $7.34 | $2.19 |
| 52 Week High | $16.24 | $13.30 |
Technical Indicators
Market Signals| Indicator | LSPD | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 56.14 |
| Support Level | $11.59 | $3.36 |
| Resistance Level | $12.34 | $3.64 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 67.02 | 78.12 |
Price Performance
Historical ComparisonAbout LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.